(a)A manufacturer of a prescription drug shall notify the department in writing if it is introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)). The notice shall be provided in writing within three days after the release of the drug in the commercial market. A manufacturer may make this notification pending approval by the federal Food and Drug Administration, if commercial availability is expected within three days of approval.
(b)No later than 30 days after notification
pursuant to this section, a manufacturer shall report all of the following information to the department in a fo
Free access — add to your briefcase to read the full text and ask questions with AI
(a)
A manufacturer of a prescription drug shall notify the department in writing if it is introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)). The notice shall be provided in writing within three days after the release of the drug in the commercial market. A manufacturer may make this notification pending approval by the federal Food and Drug Administration, if commercial availability is expected within three days of approval.
(b)
No later than 30 days after notification
pursuant to this section, a manufacturer shall report all of the following information to the department in a format prescribed by the department:
(1)
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally.
(2)
The estimated volume of patients that may be prescribed the drug.
(3)
If the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to final approval.
(4)
The date and price of acquisition if the drug was not developed by the manufacturer.
(c)
The
manufacturer may limit the information reported pursuant to subdivision (b) to that which is otherwise in the public domain or publicly available.
(d)
The department shall publish the information provided to it pursuant to this section on its internet website on no less than a quarterly basis. The information shall be published in a manner that identifies the information that is disclosed on a per-drug basis and shall not be aggregated in a manner that would not allow identification of the drug.
(e)
The department shall be responsible for the enforcement of this section.
(f)
A manufacturer of a prescription drug subject to this chapter that does not report the information required pursuant to this section is liable for a
civil penalty of one thousand dollars ($1,000) per day for every day after the notification period described in this section that the required information is not reported.
(g)
A civil penalty shall be assessed and recovered in a civil action brought by the department in the name of the people of the State of California. Assessment of a civil penalty may, at the request of any manufacturer of a prescription drug subject to this section, be reviewed on appeal, and the penalty may be reduced or waived for good cause.
(h)
Any money received by the department pursuant to this section shall be paid into the Managed Care Fund.